On behalf of Patrys Limited (ASXAB) I am pleased to share some recent industry headlines which capture significant deals in the antibody drug conjugates (ADCs) space.
Late last year, Patrys announced new data from a preclinical study that demonstrated potential for using our deoxymab antibodies as targeting agents in ADCs. This was a promising development, and one which opens up a range of possibilities for our platform in precision medicine.
ADCs harness the targeting attributes of antibodies to deliver drugs specifically to the sites of disease.
Our preclinical study has shown the affinity our deoxymabs have for DNA is sufficient for them to target the delivery of cancer drugs to tumours, where they can inhibit tumour growth and improve survival.
Some of the biggest names in pharma are now pursuing opportunities in this space too. Take a look at these recent deals:
While our focus is on advancing PAT-DX1 and PAT-DX3 as single agents for cancer, the potential upside from our work in the ADC space is truly exciting, so I hope you enjoy reading this news.
PAB Price at posting:
2.6¢ Sentiment: Buy Disclosure: Held
AB) I am pleased to share some recent industry headlines which capture significant deals in the antibody drug conjugates (ADCs) space.
